Drug firms continue to make basic errors in their electronic submissions according to French regulatory group the AFSSAPS, which said recently that it returns half the NeeS dossiers it receives as they do not meet basic validation standards.
SAFC Pharma is preparing for the shift towards cell culture-based vaccines, while still supplying and growing in the traditional sector, to ensure it can grow in coming years, according to a company director.
The impact of the economic downturn is still being felt but SAFC remains "cautiously optimistic" about 2010, believing its close relationships with clients and investment in key emerging markets will generate business.
Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.
Conducting trials in smaller patient populations when developing personalised medicines poses challenges, such as how to recruit patients fast enough, but these can be overcome using adaptive methods, according to a CEO.
AAPS 2009 has drawn to a close but over the three days numerous trends and debates emerged, including the strategies CROs are using in the downturn, and we take a look at these in our conference round up.